NEW YORK/LONDON (Reuters) – Merck & Co Inc is looking to sell a big portfolio of mature drugs that could fetch more than $15 billion (8.8 billion pounds), according to people familiar with the matter, as the U.S. drugmaker continues to streamline businesses to focus on high-growth areas.
Merck, which is also in the process of selling its $14 billion consumer healthcare unit, is working with an investment bank on the potential sale of the off-patent drugs, which could draw interest from generic drugmakers, the people said.
Read more here: https://uk.investing.com/news/stock-market-news/this-expert-sees-gold-breaking-2000-level-by-end-of-2023–heres-why-2916
